Obesity, kidney dysfunction, and inflammation: interactions in hypertension
2020/11/17 by John E. Hall, John E Hall, Alan J. Mouton +9 · 28 citations
Nursing · Medicine · #Sodium Intake and Health #Blood Pressure and Hypertension Studies #Hormonal Regulation and Hypertension
paper · doi:10.1093/cvr/cvaa336
Abstract
Obesity contributes 65-75% of the risk for human primary (essential) hypertension (HT) which is a major driver of cardiovascular and kidney diseases. Kidney dysfunction, associated with increased renal sodium reabsorption and compensatory glomerular hyperfiltration, plays a key role in initiating obesity-HT and target organ injury. Mediators of kidney dysfunction and increased blood pressure include (i) elevated renal sympathetic nerve activity (RSNA); (ii) increased antinatriuretic hormones such as angiotensin II and aldosterone; (iii) relative deficiency of natriuretic hormones; (iv) renal compression by fat in and around the kidneys; and (v) activation of innate and adaptive immune cells that invade tissues throughout the body, producing inflammatory cytokines/chemokines that contribute to vascular and target organ injury, and exacerbate HT. These neurohormonal, renal, and inflammatory mechanisms of obesity-HT are interdependent. For example, excess adiposity increases the adipocyte-derived cytokine leptin which increases RSNA by stimulating the central nervous system proopiomelanocortin-melanocortin 4 receptor pathway. Excess visceral, perirenal and renal sinus fat compress the kidneys which, along with increased RSNA, contribute to renin-angiotensin-aldosterone system activation, although obesity may also activate mineralocorticoid receptors independent of aldosterone. Prolonged obesity, HT, metabolic abnormalities, and inflammation cause progressive renal injury, making HT more resistant to therapy and often requiring multiple antihypertensive drugs and concurrent treatment of dyslipidaemia, insulin resistance, diabetes, and inflammation. More effective anti-obesity drugs are needed to prevent the cascade of cardiorenal, metabolic, and immune disorders that threaten to overwhelm health care systems as obesity prevalence continues to increase.
Citations
Cited by
- Adipose Tissue in Cardiovascular Disease: From Basic Science to Clinical Translation
- Insulin resistance: Risk factors, diagnostic approaches and mathematical models for clinical practice, epidemiological studies, and beyond
- Obesity and chronic kidney disease
- The Causes and Potential Injurious Effects of Elevated Serum Leptin Levels in Chronic Kidney Disease Patients. [europepmc]
- Modulation of Sirt1 and FoxO1 on Hypothalamic Leptin-Mediated Sympathetic Activation and Inflammation in Diet-Induced Obese Rats. [europepmc]
- Sex differences in the impact of parental obesity on offspring cardiac SIRT3 expression, mitochondrial efficiency, and diastolic function early in life. [europepmc]
- Perirenal Adipose Tissue Inflammation: Novel Insights Linking Metabolic Dysfunction to Renal Diseases. [europepmc]
- Microbiome First Medicine in Health and Safety. [europepmc]
- Role of Renal Sympathetic Nerves in GLP-1 (Glucagon-Like Peptide-1) Receptor Agonist Exendin-4-Mediated Diuresis and Natriuresis in Diet-Induced Obese Rats. [europepmc]
- Obesity-Related Glomerulopathy: From Mechanism to Therapeutic Target. [europepmc]
- Comprehensive insights in GRK4 and hypertension: From mechanisms to potential therapeutics. [europepmc]
- Burden of Aortic Aneurysm and Its Attributable Risk Factors from 1990 to 2019: An Analysis of the Global Burden of Disease Study 2019. [europepmc]
- Triglyceride-Glucose Index for the Diagnosis of Metabolic Syndrome: A Cross-Sectional Study of 298,652 Individuals Receiving a Health Check-Up in China. [europepmc]
- Association between healthy lifestyle and the occurrence of cardiometabolic multimorbidity in hypertensive patients: a prospective cohort study of UK Biobank. [europepmc]
- Inflammation, sex, blood pressure changes and hypertension in midlife: the Hordaland Health Study. [europepmc]
- Vanin 1 Gene Role in Modulation of iNOS/MCP-1/TGF-β1 Signaling Pathway in Obese Diabetic Patients. [europepmc]
- Links between Metabolic Syndrome and Hypertension: The Relationship with the Current Antidiabetic Drugs. [europepmc]
- Mechanisms and treatment of obesity-related hypertension-Part 1: Mechanisms. [europepmc]
- The neutrophil-to-lymphocyte ratio is associated with all-cause and cardiovascular mortality among individuals with hypertension. [europepmc]
- Cardiometabolic comorbidities and complications of obesity and chronic kidney disease (CKD). [europepmc]
- Sodium-Glucose Cotransporter Inhibitors: Cellular Mechanisms Involved in the Lipid Metabolism and the Treatment of Chronic Kidney Disease Associated with Metabolic Syndrome. [europepmc]
- Association between the triglyceride glucose index and the risk of acute kidney injury in critically ill patients with hypertension: analysis of the MIMIC-IV database. [europepmc]
- Association of the weight-adjusted waist index with hypertension in the context of predictive, preventive, and personalized medicine. [europepmc]
- Association between platelet to high-density lipoprotein cholesterol ratio (PHR) and hypertension: evidence from NHANES 2005-2018. [europepmc]
- Antihypertensive and antioxidant effects of food-derived bioactive peptides in spontaneously hypertensive rats. [europepmc]
- From Adipose to Ailing Kidneys: The Role of Lipid Metabolism in Obesity-Related Chronic Kidney Disease. [europepmc]
- Near-universal prevalence of central adiposity in heart failure with preserved ejection fraction: the PARAGON-HF trial. [europepmc]
- The Adipokine Hypothesis of Heart Failure With a Preserved Ejection Fraction: A Novel Framework to Explain Pathogenesis and Guide Treatment. [europepmc]
Related